Stock listing
NASDAQ:QNRX Quoin Pharmaceuticals. Ltd Stock
Follow Quoin Pharmaceuticals. Ltd into a list and get an email when it puts out news.
Share price · NASDAQ:QNRX
$3.28 USD -0.28 (-7.9%)
Close on Nov 20, 2026
- Day range
- $3.18 – $3.54 USDNov 20, 2026
- Volume
- 11,312 sharesNov 20, 2026
- Market cap
- $15.76M USDAt the close on Nov 20, 2026 · price × 4.80M shares outstanding
- 52-week range
- $3.18 – $23.50 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $3.26M USDMedian day 25,422 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:QNRX · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $3.28 | -0.28 | -7.9% | $3.50 | $3.536 | $3.18 | 11,312 | |
| $3.56 | +0.20 | +6.0% | $3.48 | $3.56 | $3.35 | 7,033 | |
| $3.36 | -0.20 | -5.6% | $3.645 | $3.645 | $3.25 | 8,241 | |
| $3.56 | -0.14 | -3.8% | $3.65 | $3.73 | $3.55 | 19,880 | |
| $3.70 | -0.05 | -1.3% | $3.99 | $3.99 | $3.55 | 16,032 | |
| $3.75 | -0.01 | -0.3% | $3.82 | $3.83 | $3.75 | 5,492 | |
| $3.76 | +0.03 | +0.8% | $3.81 | $3.81 | $3.73 | 4,259 | |
| $3.73 | -0.175 | -4.5% | $3.96 | $3.96 | $3.71 | 6,245 | |
| $3.905 | +0.255 | +7.0% | $3.74 | $3.905 | $3.74 | 3,520 | |
| $3.65 | -0.20 | -5.2% | $3.79 | $4.02 | $3.45 | 25,422 | |
| $3.85 | -0.17 | -4.2% | $3.75 | $3.97 | $3.75 | 10,892 | |
| $4.02 | +0.09 | +2.3% | $3.925 | $4.03 | $3.88 | 9,550 | |
| $3.93 | -0.09 | -2.2% | $4.11 | $4.34 | $3.901 | 20,758 | |
| $4.02 | -0.52 | -11.5% | $4.56 | $4.62 | $4.02 | 21,331 | |
| $4.54 | +0.39 | +9.4% | $4.19 | $4.54 | $3.87 | 36,600 | |
| $4.15 | +0.04 | +1.0% | $4.13 | $4.15 | $4.05 | 3,300 | |
| $4.11 | +0.06 | +1.5% | $4.07 | $4.22 | $3.911 | 6,700 | |
| $4.05 | +0.04 | +1.0% | $4.13 | $4.13 | $4.045 | 1,500 | |
| $4.01 | -0.01 | -0.2% | $3.96 | $4.21 | $3.91 | 14,900 | |
| $4.02 | +0.01 | +0.2% | $4.082 | $4.082 | $4.02 | 2,200 | |
| $4.01 | +0.02 | +0.5% | $3.92 | $4.08 | $3.91 | 11,200 | |
| $3.99 | -0.05 | -1.2% | $4.01 | $4.19 | $3.99 | 7,800 | |
| $4.04 | +0.06 | +1.5% | $4.09 | $4.135 | $3.95 | 8,100 | |
| $3.98 | +0.08 | +2.1% | $4.03 | $4.05 | $3.88 | 15,400 | |
| $3.90 | -0.13 | -3.2% | $4.00 | $4.11 | $3.90 | 31,700 | |
| $4.03 | -0.07 | -1.7% | $3.95 | $4.149 | $3.91 | 24,100 | |
| $4.10 | -0.05 | -1.2% | $4.11 | $4.29 | $3.91 | 159,400 | |
| $4.15 | -0.21 | -4.8% | $4.49 | $4.56 | $4.15 | 26,400 | |
| $4.36 | -0.14 | -3.1% | $4.83 | $5.31 | $4.30 | 50,600 | |
| $4.50 | -0.05 | -1.1% | $4.32 | $4.68 | $4.25 | 42,500 | |
| $4.55 | -0.15 | -3.2% | $4.49 | $4.70 | $4.30 | 49,000 | |
| $4.70 | -0.02 | -0.4% | $4.61 | $4.83 | $4.50 | 26,200 | |
| $4.72 | +0.165 | +3.6% | $4.48 | $4.88 | $4.35 | 103,400 | |
| $4.555 | +0.085 | +1.9% | $4.53 | $4.74 | $4.364 | 21,100 | |
| $4.47 | -0.25 | -5.3% | $4.81 | $4.81 | $4.47 | 20,300 | |
| $4.72 | +0.16 | +3.5% | $4.685 | $4.80 | $4.50 | 17,100 | |
| $4.56 | -0.32 | -6.6% | $4.88 | $5.09 | $4.55 | 139,200 | |
| $4.88 | -0.38 | -7.2% | $5.30 | $5.52 | $4.80 | 64,200 | |
| $5.26 | -1.17 | -18.2% | $6.40 | $6.41 | $5.26 | 70,300 | |
| $6.43 | +0.05 | +0.8% | $6.40 | $6.69 | $6.247 | 11,000 | |
| $6.38 | -0.37 | -5.5% | $6.83 | $7.10 | $6.12 | 39,400 | |
| $6.75 | -0.26 | -3.7% | $7.07 | $7.15 | $6.51 | 39,400 | |
| $7.01 | +0.11 | +1.6% | $6.98 | $7.161 | $6.91 | 29,300 | |
| $6.90 | -0.16 | -2.3% | $6.92 | $7.14 | $6.76 | 52,100 | |
| $7.06 | +0.05 | +0.7% | $6.85 | $7.15 | $6.70 | 15,500 | |
| $7.01 | +0.11 | +1.6% | $6.92 | $7.22 | $6.44 | 28,100 | |
| $6.90 | +0.10 | +1.5% | $6.826 | $6.99 | $6.75 | 52,100 | |
| $6.80 | -0.08 | -1.2% | $6.89 | $6.89 | $6.273 | 39,000 | |
| $6.88 | +0.09 | +1.3% | $6.71 | $6.95 | $6.66 | 10,200 | |
| $6.79 | -0.11 | -1.6% | $6.87 | $6.87 | $6.66 | 65,700 | |
| $6.90 | -0.07 | -1.0% | $6.84 | $7.00 | $6.58 | 31,000 | |
| $6.97 | -0.18 | -2.5% | $7.09 | $7.10 | $6.844 | 59,200 | |
| $7.15 | -0.11 | -1.5% | $7.33 | $7.65 | $7.05 | 196,000 | |
| $7.26 | -0.61 | -7.8% | $7.64 | $7.687 | $7.10 | 78,700 | |
| $7.87 | +1.13 | +16.8% | $6.81 | $8.00 | $6.26 | 437,100 | |
| $6.74 | +0.23 | +3.5% | $6.50 | $6.98 | $6.40 | 371,100 | |
| $6.51 | +0.29 | +4.7% | $5.90 | $6.58 | $5.75 | 275,200 | |
| $6.22 | +0.10 | +1.6% | $5.45 | $6.55 | $5.43 | 566,500 | |
| $6.12 | +0.965 | +18.7% | $7.22 | $8.25 | $5.95 | 31,017,000 | |
| $5.155 | -0.025 | -0.5% | $5.135 | $5.18 | $4.664 | 33,900 | |
| $5.18 | +0.11 | +2.2% | $5.10 | $5.33 | $5.10 | 9,900 | |
| $5.07 | -0.35 | -6.5% | $5.32 | $5.415 | $4.85 | 18,200 | |
| $5.42 | -0.15 | -2.7% | $5.395 | $6.46 | $5.329 | 31,300 | |
| $5.57 | +0.58 | +11.6% | $5.29 | $5.88 | $5.02 | 72,100 | |
| $4.99 | +0.27 | +5.7% | $4.85 | $5.225 | $4.639 | 8,100 |
Splits
5 splits since 2019 · NASDAQ:QNRX · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-35 | Consolidation | |
| 1-for-12 | Consolidation | |
| 2-for-25 | Consolidation | |
| 1-for-4 | Consolidation | |
| 1-for-5 | Consolidation |
- Ticker
- NASDAQ:QNRX
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 6, 2026
Quoin Pharmaceuticals’ Latest NETHERTON NOW Video Details the Life of a Family Living with Netherton Syndrome
Latest deck · August 2026
Investor Presentation (August 2026)
Investor deck · 26 slides
Latest news
Quoin Pharmaceuticals’ Latest NETHERTON NOW Video Details the Life of a Family Living with Netherton Syndrome
Nov 6, 2026
Closed $3.65 (-5.2%) on Nov 6, 2026
Quoin Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2026 Financial Results
Nov 5, 2026
Closed $3.85 (-4.2%) on Nov 5, 2026
Quoin Pharmaceuticals to Announce Corporate Update and Third Quarter 2026 Financial Results on Thursday, November 5, 2026
Oct 29, 2026
Closed $4.15 (+1.0%) on Oct 29, 2026
Quoin Pharmaceuticals Announces Publication of Peer-Reviewed Paper on QRX003 for Netherton Syndrome in Dermatology and Therapy
Oct 20, 2026
Closed $4.04 (+1.5%) on Oct 20, 2026
Quoin Pharmaceuticals. Ltd on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 4 in the last 12 months · 4 in all · newest Nov 6, 2026 · oldest 2026
- Calls
- 6 calls with a replay · 6 with a transcript · latest Mar 14, 2024
- Decks
- 5 decks · latest August 2026
Valuation
Price/book 0.6× against a median of 1.7×: 2nd lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$17.43M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 0.6×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 0.68
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Quoin Pharmaceuticals. Ltd · NASDAQ:QNRX | US$15.76M | −US$17.43M | n/a | n/a | n/a | 0.6× | n/a | 0.0× | 0.68 |
| SynCore Biotechnology Co., Ltd. · TPEX:4192 | US$16.80M | US$12.38M | n/a | 15.6× | n/a | 2.5× | −178.5% | 0.0× | n/a |
| Initiator Pharma A/S · OMXSTO:INIT | US$16.74M | US$15.65M | n/a | n/a | n/a | 13.4× | n/a | 1.1× | n/a |
| Neurotech International Ltd. · ASX:NTI | US$16.63M | US$15.06M | n/a | n/a | n/a | 41.1× | n/a | 0.0× | n/a |
| Akari Therapeutics PLC · NASDAQ:AKTX | US$16.41M | US$10.66M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | 1.49 |
| Lipocine Inc. · NASDAQ:LPCN | US$16.39M | −US$5.07M | n/a | −1.4× | n/a | 0.8× | −249.2% | 0.0× | 1.18 |
| MaaT Pharma · EURONEXT:MAAT | US$16.11M | US$23.36M | n/a | 4.7× | n/a | n/a | −686.6% | n/a | n/a |
| Elicera Therapeutics AB · OMXSTO:ELIC | US$16.09M | US$10.40M | n/a | n/a | n/a | 2.9× | n/a | 0.0× | n/a |
| Pasithea Therapeutics Corp. · NASDAQ:KTTA | US$16.00M | −US$25.22M | n/a | n/a | −0.1× | 0.4× | n/a | 0.0× | 0.97 |
| Atossa Therapeutics, Inc. · NASDAQ:ATOS | US$15.92M | −US$4.66M | n/a | n/a | n/a | 0.7× | n/a | 0.0× | 0.87 |
| Celularity Inc. · NASDAQ:CELU | US$15.02M | US$50.46M | n/a | 2.7× | n/a | n/a | −117.3% | n/a | 1.47 |
| Median of the others | US$16.25M | US$11.52M | 3.7× | −0.1× | 1.7× | −213.8% | 0.0× | 1.18 |
Forecasts
6 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.
- Price target
- 20.38 USD · Analysts' mean
- EPS, year to Dec 2026
- -5.25 · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Michael Myers | Co-Founder, Chairman, Chief Executive Officer and Director |
| Sally Lawlor | Chief Financial Officer |
| Denise Carter | Co-Founder, Chief Operating Officer and Director |
Board
| Director | Role |
|---|---|
| Michael Myers | Co-Founder, Chairman, Chief Executive Officer and Director |
| Denise Carter | Co-Founder, Chief Operating Officer and Director |
| Dennis H. Langer | Director |
| James Culverwell | Director |
| Joseph Cooper | Director |
| Michael Sember | Director |
| Natalie Leong | Director |
Events
Calls
| Call | When | Status |
|---|---|---|
| Quoin Pharmaceuticals. (NASDAQ:QNRX) Q4 2023 Earnings Call | Thu, Mar 14, 2024 · 8:30 AM ET | Replay |
| Quoin Pharmaceuticals. (NASDAQ:QNRX) Q3 2023 Earnings Call | Thu, Nov 09, 2023 · 8:30 AM ET | Replay |
| Quoin Pharmaceuticals. (NASDAQ:QNRX) Q2 2023 Earnings Call | Wed, Aug 02, 2023 · 8:30 AM ET | Replay |
| Quoin Pharmaceuticals. (NASDAQ:QNRX) Q1 2023 Earnings Call | Tue, May 09, 2023 · 8:30 AM ET | Replay |
| Quoin Pharmaceuticals. (NASDAQ:QNRX) Q3 2022 Earnings Call | Thu, Nov 10, 2022 · 8:30 AM ET | Replay |
| Quoin Pharmaceuticals. (NASDAQ:QNRX) Q2 2022 Earnings Call | Thu, Aug 18, 2022 · 8:30 AM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 5, 2026 · After close | −5.2% |
| Q2 2026 | Aug 14, 2026 · Before open | −15.9% |
| Q4 2025 | Mar 26, 2026 · Before open | −18.4% |
| Q3 2025 | Nov 6, 2025 · Before open | −11.2% |
| Q2 2025 | Aug 7, 2025 · After close | +3.5% |
| Q1 2025 | May 13, 2025 · After close | +20.3% |
| Q4 2024 | Mar 11, 2025 · Before open | +2.0% |
| Q3 2024 | Nov 8, 2024 · Before open | −3.3% |
| Q2 2024 | Aug 8, 2024 · After close | −5.3% |
| Q1 2024 | May 9, 2024 · After close | −2.8% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q4 2023 | Mar 13, 2024 · After close | −13.8% |
| Q3 2023 | Nov 9, 2023 · After close | −4.7% |
| Q2 2023 | Aug 3, 2023 · After close | −10.2% |
| Q1 2023 | May 9, 2023 · After close | −1.0% |
| Q4 2022 | Mar 8, 2023 · After close | −7.8% |
| Q3 2022 | Nov 10, 2022 · After close | −1.0% |
| Q2 2022 | Aug 18, 2022 · After close | −5.9% |
| Q1 2022 | Apr 14, 2022 · Before open | −0.8% |
| Q4 2021 | Mar 21, 2022 | +2.0% |
| Quarter to Sep 30, 2021 | Dec 20, 2021 · Before open | −13.6% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (August 2026) | Investor deck | 26 slides | August 2026 |
| Cellect Biotechnology — Investor Presentation (April 2019) | Investor deck | 21 slides | Apr 30, 2019 |
| Cellect Biotechnology — Investor Presentation (November 2017) | Investor deck | 22 slides | Nov 2, 2017 |
| Cellect Biotechnology — Investor Presentation (March 2017) | Investor deck | 19 slides | Mar 23, 2017 |
| Cellect Biotechnology — IPO Roadshow (July 2016) | IPO roadshow | 28 slides | Jul 25, 2016 |
IPO
Went public as Cellect Biotechnology Ltd. Priced at US$6.50 an ADS on Jul 29, 2016.
- Price
- US$6.50 an ADS
- ADSs offered
- 1,292,308 American depositary shares
- Offering size
- US$8.4 million
- Underwriters
- Rodman & Renshaw, Joseph Gunnar & Co., LLC · In the order on the cover
- ADSs delivered
- On or about Aug 3, 2016
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Apr 8, 2016 |
| Filed publicly | Jul 7, 2016 |
| Amended 5 times | Newest Jul 28, 2016 |
| Shares registered with an exchange | Jul 27, 2016 |
| Declared effective by the SEC | Jul 28, 2016 |
| Final prospectus, with the price | Aug 1, 2016 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Aug 1, 2016 |
| CERTNAS · Nasdaq's certificate of listing | Jul 29, 2016 |
| EFFECT · Notice that a registration is effective | Jul 28, 2016 |
| F-1/A · Registration statement, amended | Jul 28, 2016 |
| CORRESP · Letter to the SEC | Jul 27, 2016 |
| F-1/A · Registration statement, amended | Jul 27, 2016 |
| UPLOAD · Letter from the SEC | Jul 27, 2016 |
| 8-A12B · Registration of shares for listing on an exchange | Jul 27, 2016 |
| F-1/A · Registration statement, amended | Jul 26, 2016 |
| CORRESP · Letter to the SEC | Jul 26, 2016 |
All 24 filings
| Filing | Filed |
|---|---|
| CORRESP · Letter to the SEC | Jul 26, 2016 |
| FWP · Free writing prospectus | Jul 25, 2016 |
| F-1/A · Registration statement, amended | Jul 25, 2016 |
| CORRESP · Letter to the SEC | Jul 22, 2016 |
| F-1/A · Registration statement, amended | Jul 22, 2016 |
| UPLOAD · Letter from the SEC | Jul 13, 2016 |
| F-1 · Registration statement | Jul 7, 2016 |
| DRSLTR · Letter to the SEC with a draft | Jul 1, 2016 |
| DRS/A · Draft registration statement, amended | Jul 1, 2016 |
| UPLOAD · Letter from the SEC | Jun 17, 2016 |
| DRS/A · Draft registration statement, amended | May 26, 2016 |
| DRSLTR · Letter to the SEC with a draft | May 25, 2016 |
| UPLOAD · Letter from the SEC | May 6, 2016 |
| DRS · Draft registration statement | Apr 8, 2016 |
Open IPO · From the cover of the final prospectus (424B4) filed Aug 1, 2016
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -280.0K | -280.0K | |
| Cost of revenue | 100.8K | 100.5K | 103.4K | 103.6K | 104.1K | 104.8K | 227.1K | 125.7K | 104.2K | 89.1K |
| Gross profit | -100.8K | -100.5K | -103.4K | -103.6K | -104.1K | -104.8K | -227.1K | -280.0K | -104.2K | -280.0K |
| Research and development | 9.80M | 3.60M | 3.31M | 2.67M | 1.56M | 244.2K | 45.6K | 8.26M | 5.89M | 8.26M |
| Selling, general and administrative | 6.49M | 5.93M | 6.07M | 6.58M | 4.50M | 1.43M | 1.51M | 7.97M | 4.20M | 7.97M |
| Operating income | -16.3M | -9.53M | -9.38M | -9.26M | -6.06M | -1.67M | -1.56M | 15.3M | 10.2M | 15.3M |
| Depreciation and amortization | 100.0K | 100.0K | 103.7K | 104.0K | 104.0K | 104.0K | 227.1K | 125.7K | 104.2K | 89.1K |
| EBITDA | -16.2M | -9.43M | -9.27M | -9.15M | -5.96M | -1.57M | -1.33M | 15.4M | 10.3M | 15.4M |
| Interest expense | 0 | 714.1K | 1.09M | 47.0K | 412.3K | |||||
| Income before tax | -15.8M | -8.96M | -8.69M | -9.38M | -21.5M | -2.10M | -1.56M | 15.3M | 10.2M | 15.3M |
| Income tax | -8.95B | 22.4K | -104.0K | -12.9M | -331.3K | 1.55M | -161.1K | -1.17M | 147.9K | |
| Net income | -15.8M | -8.96M | -8.69M | -9.38M | -21.5M | -2.10M | -1.56M | 15.3M | 10.2M | 15.3M |
| Earnings per share, basic | -0.30 | -1.00 | -8.80 | -23.23 | -0.01 | -0.70 | -0.52 | |||
| Earnings per share, diluted | -0.01 | -0.70 | -0.52 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 3.82M | 3.62M | 2.40M | 2.86M | 7.48M | 323.8K | 5.24M | 4.77M | 3.96M | 1.63M |
| Short-term investments | 14.9M | 10.4M | 8.29M | 9.99M | 0 | 4.03M | 6.41M | |||
| Receivables | 77.3K | 57.8K | 70.6K | 172.0K | ||||||
| Current assets | 20.0M | 14.9M | 11.3M | 13.4M | 8.20M | 465.2K | 5.38M | 4.98M | 8.22M | 8.42M |
| Total assets | 20.4M | 15.7M | 12.2M | 14.5M | 9.36M | 1.38M | 6.17M | 5.52M | 8.75M | 8.81M |
| Accounts payable | 1.26M | 905.7K | 526.5K | 605.6K | 923.2K | 45.7K | 237.4K | 490.5K | 349.0K | |
| Current liabilities | 5.55M | 4.18M | 3.58M | 3.53M | 4.58M | 7.99M | 1.05M | 1.31M | 1.18M | 905.5K |
| Total debt | 1.21M | 310.7K | 15.1K | |||||||
| Total liabilities | 7.27M | 6.50M | 6.51M | 7.05M | 8.70M | 7.99M | 1.88M | 1.80M | 3.32M | 1.41M |
| Shareholders' equity | 13.1M | 9.20M | 5.66M | 7.41M | 657.0K | -6.61M | -4.51M | 3.73M | 5.43M | 7.40M |
| Shares outstanding | 52.4M | 8.95M | 987.2K | 403.9K | 3.35B | 1.20B | 3.35B | 62 | 53 | 43 |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -13.5M | -7.86M | -7.86M | -8.48M | -5.72M | -1.34M | -1.30M | -6.57M | -4.98M | -3.77M |
| Capital spending | -4 | 0 | -4 | -250.0K | -625.0K | -125.0K | -34.5K | -182.5K | -74.5K | -330.6K |
| Free cash flow | -13.5M | -7.86M | -7.86M | -8.73M | -6.35M | -1.46M | -5.74M | -6.76M | -5.05M | -4.10M |
| Cash from investing | -4.28M | -1.89M | 2.19M | -10.1M | -625.0K | -125.0K | -30.3K | 3.81M | 2.83M | -4.71M |
| Cash from financing | 18.0M | 11.0M | 5.22M | 14.0M | 13.5M | 1.79M | 1.30M | 3.55M | 4.43M | 9.13M |
| Dividends paid | -65.3M | |||||||||
| Share buybacks | -14.8M | |||||||||
| Change in cash | 194.8K | 1.22M | -459.4K | -4.62M | 7.16M | 323.8K | -40 | 809.8K | 2.32M | 653.5K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 16, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Nov 12, 2026 | Meeting outcome | SEC |
| 8-K · Current report | Nov 6, 2026 | Results | SEC |
| 10-Q · Quarterly report | Nov 5, 2026 | Quarterly report | SEC |
| EFFECT · Notice that a registration is effective | Nov 5, 2026 | Other filings | SEC |
| 8-K · Current report | Nov 4, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Nov 4, 2026 | Offer document | SEC |
| 424B5 · Prospectus | Nov 4, 2026 | Offer document | SEC |
| S-3 · Registration statement | Oct 27, 2026 | Offer document | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4/A · Change in ownership, amended | Oct 26, 2026 | Insider trade | SEC |
| 8-K · Current report | Oct 20, 2026 | Current report | SEC |
| 8-K · Current report | Oct 14, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 7, 2026 | Big-stake notice | SEC |
| DEF 14A · Proxy statement | Oct 2, 2026 | Meeting notice | SEC |
| EFFECT · Notice that a registration is effective | Sep 28, 2026 | Other filings | SEC |
| 424B3 · Prospectus | Sep 25, 2026 | Offer document | SEC |
| PRE 14A · Preliminary proxy statement | Sep 22, 2026 | Meeting notice | SEC |
| 8-K · Current report | Sep 22, 2026 | Current report | SEC |
| S-3 · Registration statement | Sep 18, 2026 | Offer document | SEC |
| D | Sep 10, 2026 | Other filings | SEC |
| 8-K · Current report | Sep 10, 2026 | Current report | SEC |
| 4 · Change in ownership | Sep 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 28, 2026 | Insider trade | SEC |
| 8-K · Current report | Aug 28, 2026 | Material contract | SEC |
| 8-K · Current report | Aug 20, 2026 | Management or board change | SEC |
| 8-K · Current report | Aug 14, 2026 | Results | SEC |
| 10-Q · Quarterly report | Aug 14, 2026 | Quarterly report | SEC |
| ARS · Annual report to shareholders | Jul 16, 2026 | Annual report | SEC |
| DEF 14A · Proxy statement | Jul 16, 2026 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Jul 6, 2026 | Meeting notice | SEC |
| 8-K · Current report | Jun 23, 2026 | Current report | SEC |
| 8-K · Current report | Jun 4, 2026 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Jun 2, 2026 | Big-stake notice | SEC |
| 424B3 · Prospectus | Jun 2, 2026 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| 8-K · Current report | May 7, 2026 | Results | SEC |
| 10-Q · Quarterly report | May 7, 2026 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 29, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 31, 2026 | Insider trade | SEC |
| 10-K · Annual report | Mar 26, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 26, 2026 | Results | SEC |
| 8-K · Current report | Mar 11, 2026 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 11, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 6, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 6, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 2, 2026 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Feb 2, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 28, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jan 20, 2026 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Dec 16, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Dec 15, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Dec 11, 2025 | Big-stake notice | SEC |
| 424B3 · Prospectus | Dec 5, 2025 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Dec 5, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 3, 2025 | Insider trade | SEC |
| CORRESP · Letter to the SEC | Dec 2, 2025 | Other filings | SEC |
| 8-K · Current report | Nov 17, 2025 | Management or board change | SEC |
| 8-K · Current report | Nov 12, 2025 | Current report | SEC |
| S-3 · Registration statement | Nov 7, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 6, 2025 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 27, 2025 | Big-stake notice | SEC |
| D | Oct 23, 2025 | Other filings | SEC |
| 8-K · Current report | Oct 21, 2025 | Current report | SEC |
| 4 · Change in ownership | Oct 15, 2025 | Insider trade | SEC |
| 8-K · Current report | Oct 15, 2025 | Material contract | SEC |
| 3 · Initial statement of ownership | Sep 8, 2025 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Aug 27, 2025 | Offer document | SEC |
| 8-K · Current report | Aug 27, 2025 | Management or board change | SEC |
| S-8 · Registration statement for employee plans | Aug 26, 2025 | Offer document | SEC |
| 4 · Change in ownership | Aug 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 25, 2025 | Insider trade | SEC |
| 8-K · Current report | Aug 21, 2025 | Management or board change | SEC |
| 10-Q · Quarterly report | Aug 7, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 7, 2025 | Results | SEC |
| ARS · Annual report to shareholders | Jul 17, 2025 | Annual report | SEC |
| DEF 14A · Proxy statement | Jul 17, 2025 | Meeting notice | SEC |
| 8-K · Current report | Jul 8, 2025 | Management or board change | SEC |
| PRE 14A · Preliminary proxy statement | Jul 7, 2025 | Meeting notice | SEC |
| 8-K · Current report | Jun 25, 2025 | Current report | SEC |
| 8-K · Current report | Jun 20, 2025 | Current report | SEC |
| 4/A · Change in ownership, amended | Jun 13, 2025 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Jun 13, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 4, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Jun 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 8-K · Current report | May 22, 2025 | Current report | SEC |
| 8-K · Current report | May 21, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| 8-K · Current report | May 14, 2025 | Results | SEC |
| 10-Q · Quarterly report | May 13, 2025 | Quarterly report | SEC |
| 8-K · Current report | Apr 30, 2025 | Current report | SEC |
| 8-K · Current report | Apr 4, 2025 | Current report | SEC |
| 8-K · Current report | Apr 4, 2025 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Apr 4, 2025 | Other filings | SEC |
| 8-K · Current report | Apr 2, 2025 | Current report | SEC |
| POS AM · Amendment to an effective registration | Mar 28, 2025 | Offer document | SEC |
| 8-K · Current report | Mar 20, 2025 | Current report | SEC |
| 10-K · Annual report | Mar 13, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 13, 2025 | Results | SEC |
| 8-K · Current report | Feb 27, 2025 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 14, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Feb 4, 2025 | Current report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jan 28, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jan 28, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jan 23, 2025 | Current report | SEC |
| 8-K · Current report | Jan 16, 2025 | Current report | SEC |
| 8-K · Current report | Jan 6, 2025 | Current report | SEC |
| SCHEDULE 13D · Big-stake notice | Jan 2, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D · Big-stake notice | Jan 2, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Dec 27, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 27, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 27, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 27, 2024 | Insider trade | SEC |
| 8-K · Current report | Dec 26, 2024 | Material contract | SEC |
| 424B4 · Prospectus | Dec 23, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Dec 23, 2024 | Other filings | SEC |
| 8-K · Current report | Dec 19, 2024 | Current report | SEC |
| S-1/A · Registration statement, amended | Dec 18, 2024 | Offer document | SEC |
| CORRESP · Letter to the SEC | Dec 17, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Dec 17, 2024 | Other filings | SEC |
| S-1 · Registration statement | Dec 11, 2024 | Offer document | SEC |
| 424B3 · Prospectus | Dec 11, 2024 | Offer document | SEC |
| 4 · Change in ownership | Dec 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 10, 2024 | Insider trade | SEC |
| 8-K · Current report | Dec 10, 2024 | Management or board change | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| 424B3 · Prospectus | Nov 8, 2024 | Offer document | SEC |
| 8-K · Current report | Nov 8, 2024 | Results | SEC |
| 10-Q · Quarterly report | Nov 7, 2024 | Quarterly report | SEC |
| 8-K · Current report | Oct 31, 2024 | Current report | SEC |
| DEF 14A · Proxy statement | Oct 24, 2024 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Oct 24, 2024 | Annual report | SEC |
| PRE 14A · Preliminary proxy statement | Oct 11, 2024 | Meeting notice | SEC |
| 8-K · Current report | Sep 30, 2024 | Current report | SEC |
| 4 · Change in ownership | Sep 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 5, 2024 | Insider trade | SEC |
| 8-K · Current report | Aug 13, 2024 | Results | SEC |
| 424B3 · Prospectus | Aug 12, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 8, 2024 | Quarterly report | SEC |
| 4 · Change in ownership | Jun 10, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 7, 2024 | Other filings | SEC |
| 424B3 · Prospectus | May 10, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | May 9, 2024 | Quarterly report | SEC |
| 424B3 · Prospectus | May 8, 2024 | Offer document | SEC |
| 8-K · Current report | May 3, 2024 | Current report | SEC |
| 8-K · Current report | Apr 9, 2024 | Meeting outcome | SEC |
| EFFECT · Notice that a registration is effective | Apr 4, 2024 | Other filings | SEC |
| DEFA14A · Additional proxy material | Apr 2, 2024 | Meeting notice | SEC |
| POS AM · Amendment to an effective registration | Mar 29, 2024 | Offer document | SEC |
| 10-K · Annual report | Mar 14, 2024 | Annual report | SEC |
| 8-K · Current report | Mar 13, 2024 | Results | SEC |
| 424B3 · Prospectus | Mar 8, 2024 | Offer document | SEC |
| 424B3 · Prospectus | Mar 8, 2024 | Offer document | SEC |
| 8-K · Current report | Mar 8, 2024 | Material contract | SEC |
| 424B4 · Prospectus | Mar 6, 2024 | Offer document | SEC |
| 8-K · Current report | Mar 6, 2024 | Current report | SEC |
| 424B3 · Prospectus | Mar 4, 2024 | Offer document | SEC |
| DEF 14A · Proxy statement | Feb 27, 2024 | Meeting notice | SEC |
| EFFECT · Notice that a registration is effective | Feb 15, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Feb 14, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Feb 14, 2024 | Other filings | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 13, 2024 | Big-stake notice | SEC |
| UPLOAD · Letter from the SEC | Feb 13, 2024 | Other filings | SEC |
| S-1/A · Registration statement, amended | Feb 13, 2024 | Offer document | SEC |
| PRE 14A · Preliminary proxy statement | Feb 13, 2024 | Meeting notice | SEC |
| S-1 · Registration statement | Feb 12, 2024 | Offer document | SEC |
| 424B3 · Prospectus | Jan 30, 2024 | Offer document | SEC |
| 8-K · Current report | Jan 30, 2024 | Material contract | SEC |
| 424B3 · Prospectus | Dec 18, 2023 | Offer document | SEC |
| 8-K · Current report | Dec 18, 2023 | Current report | SEC |
This page holds 200 of 587 filings. Open Filings
Cap table
Built by 6ix from Quoin Pharmaceuticals. Ltd’s releases
- Common shares
- 4,804,161
- Fully diluted
- 4,804,161
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 4,804,161 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 4,804,161 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Dennis Langer Other companies: Ernexa Therapeutics Inc. (Director · May 1, 2021 – Dec 8, 2021 · Past); Pernix Therapeutics Holdings Inc (Director · Nov 4, 2016 – May 22, 2018 · Past); Delcath Systems, Inc. (Director · Dec 11, 2014 – Jun 10, 2015 · Past); Dicerna Pharmaceuticals Inc (Director · Sep 24, 2013 – Jun 20, 2019 · Past); Myrexis Inc (Director · Dec 8, 2011 – Dec 8, 2011 · Past); Myriad Genetics, Inc. (Director · Dec 2, 2011 – Jun 30, 2022 · Past) | Director · Since at least Jan 1, 2023 |
| Joseph Cooper Other companies: Bioenvision Inc (Director · Oct 6, 2006 – Jan 3, 2007 · Past); Medicis Pharmaceutical Corp (EVP,Corp & Product Development · Jul 10, 2006 – Apr 4, 2010 · Past) | Director · Since at least Jan 1, 2023 |
| Michael Sember Other companies: Iomed Inc (Director · Nov 9, 2006 – Aug 9, 2007 · Past); Soligenix, Inc. (Chief Executive Officer, Director · Apr 10, 2006 – Apr 10, 2006 · Past) | Director · Since at least Jan 1, 2023 |
| Anthony James Culverwell | Director · Since at least Jan 1, 2023 |
| Denise Carter | Co-Founder, Chief Operating Officer and Director · Since at least Jan 1, 2023 |
| Gordon Dunn | Chief Financial Officer · Jan 1, 2023 – Dec 23, 2024 · Past |
| James Culverwell | Director · Since at least Nov 4, 2026 |
| Michael Myers | Co-Founder, Chairman, Chief Executive Officer and Director · Since at least Jan 1, 2023 |
| Natalie Leong | Director · Since at least Nov 4, 2026 |
| Sally Lawlor | Chief Financial Officer · Since at least Aug 18, 2025 |
Log in to ask 6ix AI your own questions about Quoin Pharmaceuticals. Ltd.